Olaratumab Plus Doxorubicin in Advanced Soft Tissue Sarcoma
William D. Tap, MD, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results from a phase Ib/II presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
This study looked at the combination of olaratumab and doxorubicin compared with doxorubicin alone as treatment for patients with advanced soft tissue sarcoma. The combination showed a 50% improvement in progression-free survival and an 11.8-month increase in overall survival.
Based on this study, the monoclonal antibody is being investigated in an ongoing phase III study and has received an FDA Breakthrough Therapy Designation.
First-in-Class Drug AMG 193 Exploits Tumor Weakness for Targeted Therapy
September 17th 2024In a first-in-human trial, AMG 193, a drug targeting a specific mutation in tumors, showed promising results in reducing tumor size and spread in various cancers, with an acceptable safety profile.
Read More
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
September 16th 2024Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib showed potential as a novel approach for patients with HR+/HER2+ breast cancer.
Read More
